Focus of the event
This event provides an open forum for debate and action on drug discovery. We focus diverse minds on major challenge including delivery of sustainable healthcare systems which demand provision of advanced and affordable diagnostics and therapeutics to millions of people living in diverse environments.
Finding useful solutions to such complex issues requires working together in new ways as a collaborative community, and is our goal. Integration of insights from the computational, life and physical sciences and social and economic spheres is needed and starts with developing mutual understanding and trust.
We welcome anyone interested in learning about and participating in our open discussion to help define the nature of the global problems we face and search for innovative solutions by working together.
Chas Bountra is the Professor of Translational Medicine in the Nuffield Department of Clinical Medicine at the University of Oxford, and advises government, charitable research funding bodies, and pharma drug discovery programmes. He was previously Vice President and Head of Biology at GlaxoSmithKline, and leads the Structural Genomics Consortium in the UK to develop small molecule inhibitors for novel targets for drug discovery.
Sam Butterworth is a Lecturer in Medicinal Chemistry in the School of Pharmacy at the University of Birmingham, which he joined after running discovery projects through collaborations, high throughput screening, and lead development at AstraZeneca, culminating in the clinical use of a kinase targeted anti-cancer agent AZD9291 for late stage lung cancer.
Charlie Craddock established the Institute for Translational Medicine through the Government's City Deal and a partnership between University Hospitals Birmingham and the University of Birmingham, which provides a world class environment for interaction between clinical academics, triallists, stratified medicine teams and the pharmaceutical sector.
Aysha Ali is studying chemistry and biotechnology as a PhD student in the Midlands Integrative Biosciences Training PartnershipDoctorate scheme which links the universities of Warwick, Birmingham and Leicester, and is interning at Science Capital to organise meetings and write an accesible guidebook for anyone interested in running a Science Capital-style event.
John Rainford is Director of Rapid Innovation at the Birmingham City University, and teaches technology entrepreneurship and marketing at BCU and the University of Birmingham. He facilitates business transformation through innovation and critical analysis using the Darwinian Innovation Matrix, and directs Strawberry Fields to support strategic business planning.
Michael Overduin, founder of Science Capital, heads a lab at the University of Alberta focussing on the mechanisms of proteins involved in signaling and trafficking in cancer and bacterial cells. He established the Henry Wellcome Building for Biomolecular NMR Spectroscopy in Birmingham and is now leading the Canadian national NMR centre, NANUC. He set up the UK Drug Discovery Initiative, and is now forming DiscoveryLAB in Edmonton.
Pitch your plan
Obtain feedback on your business idea and explore new partnerships.
Scientists, clinicians, start-ups and SMEs are invited to present their plans for a free private consultation during the afternoon with a panel of legal, business, financial and investment advisors who are experienced in developing commercialisation strategies.
Pro-bono support is available to presenters from firms including FD Solutions, HGF, Quarto Perspective and Wragge & Co. Places are limited, so register below soon to secure your place.
People will gather at 5:30pm for a canape and drinks reception, to view posters and exhibitor stands, and meet colleagues.
Talks begin at 6pm, and are followed by lively panel discussions. Dinner will be served from 8-9:30pm.
Business plans are pitched to our panel of experts from 3-5pm.
Save This Event
When & Where
Science Capital brings together people who are interested in working together to address major challenges by exploring new solutions and developing innovative technologies.
We are independent and inclusive. You are welcome to subscribe at no cost or obligation. See www.sciencecapital.co.uk or contact Michael Overduin at firstname.lastname@example.org.
Please enquire by contacting:
Packages are described at:
Science Capital, c/o FD Solutions, 1 Victoria Square, Birmingham, B1 1BD